PositiveID Corporation (OTCBB:PSID) develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MFS, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays.

1. detection and diagnostics
InvestorIdeas.com
Security and Defense Conference
March 2014

2. Forward-Looking Statements
Information contained in this presentation may contain forward-looking statements, including,
but not limited to: PositiveID’s ability to participate in the BioWatch Generation 3 opportunity and
PositiveID’s ability to complete development and commercialization of Firefly. These forwardlooking statements are not statements of historical fact and represent only PositiveID
Corporation's beliefs regarding future performance, which is inherently uncertain. There are a
variety of factors, many of which are beyond the control of PositiveID Corporation, which affect
operations, performance, business strategy and results and could cause actual results and
experience to differ materially from the expectations and objectives expressed in any forwardlooking statements. Additional information about these and other factors that could affect
PositiveID Corporation's business is set forth in PositiveID Corporation's various filings with the
Securities and Exchange Commission, including those set forth in PositiveID Corporation's Form
10-K filed on April 16, 2013, and Forms 10-Q filed on May 20, 2013 and August 14, 2013, as
amended on August 19, 2013, and November 19, 2013, under the caption "Risk Factors."
PositiveID Corporation undertakes no obligation to update or release any revisions to these
forward-looking statements to reflect events or circumstances after the date of this statement or
to reflect the occurrence of unanticipated events, except as required by law.
2

3. Overview
 PositiveID Corporation develops molecular diagnostic
systems for bio-threat detection and rapid medical testing
 Strong IP portfolio - 20 patents and patents pending
 Two innovative products: the first positioned for large
Department of Homeland Security (“DHS”) next generation
bio detection system; the second developed for large
commercial/diagnostic markets
 Initial technology developed with $30M in funding from DHS
 PSID has been selected by Boeing and SAIC/Leidos as a
technology and license partner
 Strong management team
3

4. M-BAND
4

5. M-BAND
Sample Prep
Single Board
Computer
Archive
Air Collector
Air
Conditioner
Reagent Chiller
Toxin
Reagent Bay
PCR
Uninterruptable
Power Supply
Additional
Reagents
5

6. M-BAND
M-BAND Integrated Pathogen Detection Systems

Developed under DHS BAND program specifically for the
next generation of BioWatch

Autonomous 24/7 operation for detection of airborne
bacteria, viruses and toxins to help thwart a biological attack

Monthly service interval

Complex modules are “smart”
−
−

Autonomous; internal processors with embedded firmware
High-level command and data interface structures
Easy field replacement and system upgrades
−
−
Key modules accessible from front of unit
All interfaces connected

Fully networked with remote access and event notification

Protected by a portfolio of 13 key patents and 3 patents
pending.
6

7. M-BAND Advantages
 M-BAND is the only product to successfully complete
development and testing under the DHS BAND program
 Operates continuously for up to 30 days between servicing
 Only known competitor is Lawrence Livermore National
Laboratory’s APDS, licensed by Northrup Grumman, which
requires weekly service – drastically increasing the total cost of
ownership
 Complete integration of sample collection through toxin and
pathogen detection and reporting of results
 Detects in 3-6 hours vs. 36-48 hours for currently deployed
systems, ability to drastically minimize loss of life
 Uses TaqMan®-based PCR chemistry, the CDC as goldstandard
 TaqMan® assay used by U.S. Postal Service to detect
anthrax
- Over 7 million tests – no false positives
- Extraordinary record is primary reason why other government
agencies have selected TaqMan® technology
7

8. M-BAND Market Opportunities

Next Generation BioWatch System


Boeing paid PositiveID $2.5 million license fee; Boeing to be exclusive
manufacturer and distributor of M-BAND units in North America

PositiveID is exclusive provider of reagents/assays to Boeing for all MBAND units built and sold; long-term annuity (monthly)

BioWatch next generation procurement anticipates 2,500 units to be
deployed over 2014-2019; units will require monthly reagent/assay
replacement

2,500 units could provide recurring revenue base of between $90-120M
revenue annually, with 15-20% net margins


Total value of next generation BioWatch system is estimated by DHS at
$3 - $5 billion over five years
One of two proven technologies that meets the needs of BioWatch next
gen autonomous detection requirement
Other opportunities

Non-licensed markets: SAIC/Leidos DTRA contract, Europe, Asia, Middle East

The annual global bio-detection market is forecast to grow to $5.6 billion by 2016 at a CAGR of 12% from
2011-2016*
* According to Homeland Security Research Corporation (HSRC)’s Bio-Detection HLS-HLD Technologies & Global Markets – 2011-2016
8

9. Firefly Dx Overview

Miniaturized version of M-BAND using same patented technologies
and real-time TaqMan PCR detection

Hand-held detection system provides sample purification, biological
analysis and wireless communication of results in 15-30 minutes

Data will be processed in real time and communicated to smart-phone
(or PC) using mobile applications and cloud storage

Single-use, portable disposable cassettes designed for resource
limited areas and minimally trained personnel
Advantages
 Cost-effective, fast results with high integrity (15-30min)
 Small operating footprint
 Enables more effective pre-outbreak counter-measures
Applications
 Environmental bacteria, e.g. E. coli
 Clinical samples, e.g. HPV
 Antibiotic-resistant bacteria, e.g. MRSA
 Biothreat agents and forensic applications
Sample Types Processed
 Blood, nasal swabs, buccal swabs, simulated urine, environmental
9
9

10. Firefly Market Opportunities
 Government/military deployments
 In discussions with several government agencies for biodosimetry
application to test for radiation in blood samples
 Food safety/agricultural
 Global market for food safety testing projected to reach $19.7B by
2018*
 Medical/clinical
 Cancer and infectious disease market exceeds $4.6B**
 MRSA market continues to grow in U.S.; present in almost 80% of
hospitals over 150 beds and 50% of smaller hospitals
 Respiratory infection and soft tissue infection have a combined market
of $1.5B
 Women’s health market (STDs including CT/NG, HIV, HPV; Strep B)
has a combined market size of $1.5B***
 The global PCR market is projected to reach approx. $27.4B by 2015,
with a CAGR of 13.9% from 2009-2015
 North America is estimated as the largest market with a market share of 40% of
global market and projects $10.7B by end-2010.
*Global Industry Analysts Report , Food Safety Testing - A Global Strategic Business Report
**Qiagen Corporate presentation 2008; Kalorama MDx Major World Markets 2007; TSG MDx Strategic Opportunities 2009
*** Hologic JP Morgan Presentation 2009
10

11. Investment Highlights

Two exciting products based on patented and patent-pending technologies
addressing large markets

Unique positioning as one of only two technologies capable of addressing
the requirements of next-gen automated BioWatch system, a $3 - $5 billion
procurement

Boeing signed exclusive license to manufacture M-BAND for BioWatch, paid
PositiveID $2.5M; PositiveID will be exclusive provider of monthly
reagents/assays for M-BAND units (annual market of $90M-$120M)

Firefly market opportunity is vast; the global PCR market is projected to
reach approx. $27.4B by 2015; food safety testing projected to reach
$19.7B by 2018
 Company believes it is ahead of competition with Firefly and expects field testing
within 12 months of beginning build

Strong management/partners/scientists with proven track records
11